-
公开(公告)号：US20120177596A1
公开(公告)日：2012-07-12
申请号：US13288299
申请日：2011-11-03
IPC分类号： A61K39/395 , A61P1/00 , A61P1/04 , A61K38/20
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
公开(公告)号：US5332571A
公开(公告)日：1994-07-26
申请号：US613518
申请日：1990-11-02
申请人： Joachim Kempeni , Michael Kluge , Walter Fiers
发明人： Joachim Kempeni , Michael Kluge , Walter Fiers
CPC分类号： A61K38/191
摘要： The enhancement of the antitumor action of tumor necrosis factor by lithium salts is described.
摘要翻译： PCT No.PCT / EP90 / 00324 Sec。 371日期1990年11月2日 102（e）1990年11月2日日期PCT提交1990年2月27日PCT公布。 出版物WO90 / 10455 1990年9月20日。描述了锂盐对肿瘤坏死因子的抗肿瘤作用的增强。
-
3.发明授权Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 失效使用抗TNF抗体作为治疗血清白细胞介素-6升高的疾病的药物公开(公告)号：US06235281B1
公开(公告)日：2001-05-22
申请号：US08687328
申请日：1996-08-07
申请人： Roswitha Stenzel , Martin Kaul , Lothar Daum , Joachim Kempeni , Christa Raab , Sibylle Schaefer
发明人： Roswitha Stenzel , Martin Kaul , Lothar Daum , Joachim Kempeni , Christa Raab , Sibylle Schaefer
IPC分类号： A61K39395
CPC分类号： C07K16/241 , A61K38/00
摘要： The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
摘要翻译： 本发明涉及TNF拮抗剂用于制备用于治疗特征为白细胞介素-6血清水平升高的疾病的药物的用途。
-
公开(公告)号：US08889135B2
公开(公告)日：2014-11-18
申请号：US10163657
申请日：2002-06-05
IPC分类号： A61K39/395 , C07K16/24 , A61K39/00
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
公开(公告)号：US20150023982A1
公开(公告)日：2015-01-22
申请号：US14498952
申请日：2014-09-26
IPC分类号： C07K16/24
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
-
公开(公告)号：US20130004507A1
公开(公告)日：2013-01-03
申请号：US13530363
申请日：2012-06-22
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
